Oncology Corporate Profile
Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|glufosfamide||alkylator-glucose conjugate||1st line metastatic Pancreatic cancer||III|
|TH-302||hypoxia-activated prodrug (HAP)||1st line metastatic soft tissue Sarcoma||III|
|TH-302||hypoxia-activated prodrug (HAP)||1st line metastatic Melanoma||II|
|TH-302||peg-GCSF||1st line metastatic Pancreatic cancer||II|
|TH-302 (+ pemetrexed)||hypoxia-activated prodrug (HAP)||Non Small Cell Lung Cancer (NSCLC)||II|
|TH-4000||EGFR tyrosine kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|TH-302 (+ sunitinib)||hypoxia-activated prodrug (HAP)||1st line metastatic Renal cell carcinoma (RCC)||I|
|TH-302||hypoxia-activated prodrug (HAP)||2nd line metastatic Glioma||I|
|TH-302||hypoxia-activated prodrug (HAP)||Astrocytoma||I|
|TH-302 (+ sunitinib)||hypoxia-activated prodrug (HAP)||Gastrointestinal Stromal Tumors (GIST)||I|
|TH-302 (+ bevacizumab)||hypoxia-activated prodrug (HAP)||Glioblastoma Multiforme (GBM)||I|
|TH-302 (+ sorefanib)||hypoxia-activated prodrug (HAP)||Hepatocellular carcinoma (HCC)||I|
|TH-302||hypoxia-activated prodrug (HAP)||Multiple Myeloma||I|
|TH-302 (+ sunitinib)||hypoxia-activated prodrug (HAP)||Pancreatic neuroendocrine tumors||I|
|2-deoxyglucose||glucose analog (synthetic)||Various cancer types||I|
|TH-302||hypoxia-activated prodrug (HAP)||Various cancer types||I|
View additional information on product candidates here »
10/25/2016 12:33 pm
(Yahoo! Finance) Oct 25, 2016 - Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for the treatment of cancer, today announced that they have entered into a development and commercialization agreement to utilize Caris’ patented and proprietary ADAPT Biotargeting System™ to develop a tissue-based clinical diagnostic assay for pancreatic cancer patients to predict the likelihood of response to evofosfamide, Threshold’s lead drug candidate for the potential treatment of patients with cancer.
6/15/2016 11:05 am
(Wall Street Journal) June 15, 2016 - Twenty-five years after classifying coffee as a possible carcinogen leading to bladder cancer, the World Health Organization’s cancer research arm has reversed course, saying on Wednesday that coffee is not classifiable as a carcinogen.
6/6/2016 05:31 pm
(Threshold) June 6, 2016 - Presentation of additional subset data from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer demonstrates meaningful improvement in overall survival in patients from Asia; risk of death reduced by almost 50 percent.
2/18/2016 12:03 pm
(Bloomberg) Feb 17, 2016 - One-third of clinical trials conducted at 51 major U.S. universities and academic hospitals were never published in a peer-reviewed journal or in a government registry online, according to a new study in the BMJ, formerly the British Medical Journal.
2/17/2016 12:01 pm
(RAPS.org) Feb 16, 2016 - The US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) met Tuesday to discuss updates of research programs in the Office of Cellular, Tissue and Gene Therapy (CTGT), which is part of FDA’s Center for Biologics Evaluation and Research (CBER).
1/11/2016 06:55 am
(CNN Money) Jan 11, 2016 - Threshold Pharmaceuticals, Inc. today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold.
12/21/2015 11:58 am
(CNNMoney) Dec 18, 2015 - Threshold to focus on clinical trials of tarloxotinib while evaluating potential further development of evofosfamide and other strategic options for the company.
12/7/2015 05:14 pm
(Reuters) Dec 7, 2015 -Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms.
12/7/2015 06:49 am
(CNNMoney) Dec 7, 2015 - Studies of evofosfamide combined With chemotherapy in advanced pancreatic cancer (MAESTRO) and advanced soft tissue sarcoma (TH-CR-406/SARC021) did not meet primary endpoints of improving overall survival with statistical significance.
11/18/2015 11:54 am
(CNNMoney) Nov 18, 2015 - Threshold Pharmaceuticals, Inc. today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012.
8/27/2015 11:46 am
(MarketWatch) Aug 27, 2015 - Threshold Pharmaceuticals, Inc. today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
8/11/2015 11:51 am
(CNN Money) Aug 11, 2015 - Threshold Pharmaceuticals, Inc. today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation.
7/27/2015 12:00 pm
(New York Times/Well blog) July 23, 2015 - Decades ago, when physicians worked within a much more paternalistic system, “doctor shopping” by patients would have been considered inappropriate. Now it has become a routine part of my practice.
7/27/2015 12:00 pm
(New York Times) July 24, 2015 - Federal regulators on Friday approved the first of a new class of drug that can sharply lower cholesterol levels, offering a new option for millions of Americans suffering from cardiovascular disease, the nation’s leading killer.
7/10/2015 11:04 am
(NBC News) July 9, 2015 - The Food and Drug Administration is strengthening its warnings about painkillers like ibuprofen, saying they do raise the risk of heart attack or stroke.
5/31/2015 07:01 pm
(Xconomy New York) May 31, 2015 - Celldex Therapeutics grabbed the spotlight late last year when an experimental vaccine it’s been developing helped extend the lives of some patients with an aggressive, deadly form of brain cancer.
5/31/2015 07:00 pm
(Threshold) May 31, 2015 - Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide (an investigational compound formerly known as TH-302) in combination with the proteasome inhibitor Velcade® (bortezomib) and low-dose dexamethasone ("EBorD") in patients with relapsed/refractory multiple myeloma.
5/28/2015 12:02 pm
(StreetInsider) May 28, 2015 - Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.
5/28/2015 12:02 pm
(Yale News) May 28, 2015 - For many cancer survivors, a better quality of life is as close as the nearest pair of sneakers. That’s because a growing body of research, including two recent studies led by Yale Cancer Center, show that exercise is a powerful way for survivors to improve quality of life.
5/15/2015 12:31 pm
(MarketWatch) May 15, 2015 - Additional data show Prolaris changed treatment plans in 48 percent of cases.
5/14/2015 01:18 pm
(Yahoo! Finance) May 13, 2015 - Threshold Pharmaceuticals, Inc. today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade®) and dexamethasone in patients with relapsed/refractory multiple myeloma.
5/12/2015 11:13 am
(Fox News.com/Reuters) May 12, 2015 - Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.
5/12/2015 07:07 am
(CNN Money) May 12, 2015 - Threshold Pharmaceuticals, Inc. today announced that the FDA has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
4/29/2015 12:00 pm
(Washington Post) Apr 28, 2015 - GSK says new shingles vaccine shows effectiveness across all age ranges, even those in their 70s.
4/22/2015 11:26 am
(NASDAQ) Apr 22, 2015 - Threshold Pharmaceuticals, Inc. today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) suggesting that TH-4000 may overcome resistance to therapy with conventional EGFR-TKIs.
4/14/2015 12:00 pm
(FoxNews.com) Apr 14, 2015 - Scientists have discovered a new type of technology that senses compounds in exhaled breath that can be used as a screening tool to detect stomach cancer.
3/30/2015 06:04 am
(Novartis) Mar 30, 2015 - Novartis announced today that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD.
3/26/2015 11:05 am
(Medscape Medical News) Mar 25, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine.
3/16/2015 07:00 am
(Bloomberg) Mar 13, 2015 - The doctors who treat Medicare patients would avoid a cut in their government reimbursements under a proposal to be presented to U.S. House members next week, according to Republican and Democratic aides.
3/13/2015 11:03 am
(Medscape Medical News) Mar 12, 2015 - The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.
2/23/2015 12:01 pm
(Reuters) Feb 23, 2015 - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.
2/19/2015 12:02 pm
(PharmaTimes [UK]) Feb 15, 2015 - A ground-breaking ‘breath test’ for lung cancer is about to go into clinical trials at Glenfield Hospital in Leicester, UK.
1/29/2015 11:01 am
(Harvard Medical School) Jan 28, 2015 - An existing drug may help some patients with non-small cell lung cancer (NSCLC) whose tumors have become resistant to chemotherapy, according to lab studies by Harvard Medical School researchers at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
1/28/2015 12:00 pm
(Washington Post/Speaking of Science) Jan 28, 2015 - The eggs were used as a proxy for a much more serious endeavor: making cancer research more time and cost efficient.
1/6/2015 12:00 pm
(San Francisco Business Times) Jan 6, 2015 - CytomX Therapeutics Inc. grabbed $20 million from Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio.
1/6/2015 12:00 pm
(TheStreet) Jan 6, 2015 - Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
11/17/2014 11:18 am
(MarketWatch) Nov 17, 2014 - 64% of patients achieved stable disease or tumor shrinkage on combination therapy following progression on single-agent bevacizumab; U.S. FDA set to fund phase 2 investigator-sponsored trial.
11/11/2014 07:24 am
(Yahoo! Finance) Nov 11, 2014 - Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).
11/3/2014 11:59 am
(Yahoo! Finance) Nov 3, 2014 - Threshold Pharmaceuticals, Inc., today announced that its partner Merck KGaA, Darmstadt, Germany, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
9/29/2014 09:05 am
(Cardinal Health) Sept 29, 2014 - Cardinal Health Specialty Solutions and KEW Group, Inc., a privately held oncology services company, today announced an agreement for the two companies to make KEW's state-of-the-art diagnostic services available to Specialty Solutions' community oncology customers.
9/29/2014 09:01 am
(CNN Money) Sept 27, 2014 - AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
9/29/2014 09:01 am
(ESMO) Sept 29, 2014 - Phase II studies with vintafolide, dabrafenib and neratinib.
9/29/2014 09:01 am
(CNBC) Sept 28, 2014 - A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).